{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:38:07Z","timestamp":1792690687584,"version":"4.5.0"},"reference-count":214,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ymthe.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:23:30Z","timestamp":1741782210000},"page":"2172-2191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in\u00a0vivo gene therapy"],"prefix":"10.1016","volume":"33","author":[{"given":"Julia","family":"Ball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Tisdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-8991","authenticated-orcid":false,"given":"Naoya","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.016_bib1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle Cell Disease","volume":"376","author":"Piel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.110.2865.543","article-title":"Sickle cell anemia a molecular disease","volume":"110","author":"Pauling","year":"1949","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib3","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/178792a0","article-title":"A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin","volume":"178","author":"Ingram","year":"1956","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib5","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.stem.2021.01.001","article-title":"Hematopoietic-Stem-Cell-Targeted Gene-Addition and Gene-Editing Strategies for \u03b2-hemoglobinopathies","volume":"28","author":"Drysdale","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2025.03.016_bib7","series-title":"FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease [News Release]","author":"Pflaum","year":"2023"},{"key":"10.1016\/j.ymthe.2025.03.016_bib8","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1182\/blood.2019003776","article-title":"Gene therapy for sickle cell disease: moving from the bench to the bedside","volume":"138","author":"Abraham","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib9","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood-2006-04-015859","article-title":"Fetal hemoglobin silencing in humans","volume":"108","author":"Oneal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1056\/NEJM198801143180207","article-title":"Levels of fetal hemoglobin necessary for treatment of sickle cell disease","volume":"318","author":"Noguchi","year":"1988","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib11","first-page":"1","article-title":"Mechanism of action of hydroxyurea","volume":"19","author":"Yarbro","year":"1992","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000040964","article-title":"Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy","volume":"102","author":"Saleh","year":"1999","journal-title":"Acta Haematol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V","article-title":"Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential","volume":"58","author":"Niihara","year":"1998","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib15","series-title":"ENDARI (L-Glutamine Oral Powder ) [package Insert]","author":"Emmaus Medical","year":"2017"},{"key":"10.1016\/j.ymthe.2025.03.016_bib16","series-title":"OXBRYTA (Voxelotor) [package Insert]","author":"Global Blood Therapeutics","year":"2019"},{"key":"10.1016\/j.ymthe.2025.03.016_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib18","article-title":"FDA Is Alerting Patients and Health Care Professionals about the Voluntary Withdrawal of Oxbryta from the Market Due to Safety Concerns","year":"2024"},{"key":"10.1016\/j.ymthe.2025.03.016_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-019-01254-2","article-title":"Crizanlizumab: First Approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.03.016_bib20","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood.V98.6.1955","article-title":"P-selectin mediates the adhesion of sickle erythrocytes to the endothelium","volume":"98","author":"Matsui","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib22","article-title":"Adakveo - Referral","year":"2023"},{"key":"10.1016\/j.ymthe.2025.03.016_bib23","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/bmt.2011.245","article-title":"Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'whom, when and how'","volume":"47","author":"Freed","year":"2012","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.ymthe.2025.03.016_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.bmt.1705943","article-title":"Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future","volume":"41","author":"Bhatia","year":"2008","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.ymthe.2025.03.016_bib25","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.hoc.2014.08.014","article-title":"Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions","volume":"28","author":"Fitzhugh","year":"2014","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"10.1016\/j.ymthe.2025.03.016_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-4939-7299-9_4","article-title":"Allogeneic\/Matched Related Transplantation for \u03b2-Thalassemia and Sickle Cell Anemia","volume":"1013","author":"Bernaudin","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjh.13352","article-title":"Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease","volume":"169","author":"Strocchio","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib28","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib29","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib30","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib31","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib32","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/bloodadvances.2016002972","article-title":"Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT","volume":"1","author":"Fitzhugh","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.016_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400192","article-title":"Haploidentical Bone Marrow Transplantation for Sickle Cell Disease","volume":"4","author":"Kassim","year":"2025","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ymthe.2025.03.016_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1479-0556-2-9","article-title":"The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery","volume":"2","author":"Anson","year":"2004","journal-title":"Genet. Vaccin. Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.016_bib36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1146\/annurev.bi.58.070189.004055","article-title":"Eukaryotic transcriptional regulatory proteins","volume":"58","author":"Johnson","year":"1989","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ymthe.2025.03.016_bib37","doi-asserted-by":"crossref","first-page":"8150","DOI":"10.1128\/JVI.72.10.8150-8157.1998","article-title":"Development of a self-inactivating lentivirus vector","volume":"72","author":"Miyoshi","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41434-022-00335-4","article-title":"HIV- 1 lentivirus tethering to the genome is associated with transcription factor binding sites found in genes that favour virus survival","volume":"29","author":"Suleman","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib39","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/gt.2011.63","article-title":"Optimal conditions for lentiviral transduction of engrafting human CD34+ cells","volume":"18","author":"Uchida","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib40","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/mt.2012.159","article-title":"High-efficiency transduction of rhesus hematopoietic repopulating cells by a modified HIV1-based lentiviral vector","volume":"20","author":"Uchida","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib41","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.ymthe.2019.05.022","article-title":"Busulfan Combined with Immunosuppression Allows Efficient Engraftment of Gene-Modified Cells in a Rhesus Macaque Model","volume":"27","author":"Uchida","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omtm.2017.10.001","article-title":"Interactions between Retroviruses and the Host Cell Genome","volume":"8","author":"Poletti","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib44","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib45","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1038\/s41467-022-31344-x","article-title":"Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency","volume":"13","author":"De Ravin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib46","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib47","first-page":"1","article-title":"T cell malignancies after CAR T\u00a0cell therapy in the DESCAR-T registry","author":"Dulery","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib48","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib49","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1568-7864(02)00110-6","article-title":"Analysis of mouse Rad54 expression and its implications for homologous recombination","volume":"1","author":"Essers","year":"2002","journal-title":"DNA Repair"},{"key":"10.1016\/j.ymthe.2025.03.016_bib50","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1073\/pnas.93.3.1156","article-title":"Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain","volume":"93","author":"Kim","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.016_bib51","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.2028256","article-title":"Zinc Finger-DNA Recognition: Crystal Structure of a Zif268-DNA Complex at 2.1\u00a0\u00c5","volume":"252","author":"Pavletich","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib52","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1534\/genetics.110.120717","article-title":"Targeting DNA double-strand breaks with TAL effector nucleases","volume":"186","author":"Christian","year":"2010","journal-title":"Genetics"},{"key":"10.1016\/j.ymthe.2025.03.016_bib53","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature03630","article-title":"R gene expression induced by a type-III effector triggers disease resistance in rice","volume":"435","author":"Gu","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib54","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib55","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nature13579","article-title":"Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease","volume":"513","author":"Anders","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib56","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.7150\/thno.43465","article-title":"A review of emerging physical transfection methods for CRISPR\/Cas9-mediated gene editing","volume":"10","author":"Fajrial","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2025.03.016_bib57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ymthe.2018.10.008","article-title":"Optimization of CRISPR\/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements","volume":"27","author":"Lattanzi","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib58","article-title":"Preclinical evaluation for engraftment of CD34(+) cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models","volume":"2","author":"Uchida","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib59","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib60","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u00b7T to G\u00b7C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/331035a0","article-title":"Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells","volume":"331","author":"Dzierzak","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib63","doi-asserted-by":"crossref","first-page":"10159","DOI":"10.1093\/nar\/15.24.10159","article-title":"Evidence for a locus activation region: the formation of developmentally stable hypersensitive sites in globin-expressing hybrids","volume":"15","author":"Forrester","year":"1987","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.016_bib64","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0092-8674(87)90584-8","article-title":"Position-independent, high-level expression of the human beta-globin gene in transgenic mice","volume":"51","author":"Grosveld","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.016_bib65","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1073\/pnas.92.15.6728","article-title":"Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene","volume":"92","author":"Sadelain","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.016_bib66","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1182\/blood-2002-10-3305","article-title":"A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer","volume":"101","author":"Rivella","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib67","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1038\/s41467-019-12456-3","article-title":"Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders","volume":"10","author":"Uchida","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib68","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00006254-194812000-00022","article-title":"THE SIGNIFICANCE OF THE PAUCITY OF SICKLE CELLS IN NEWBORN NEGRO INFANTS","volume":"3","author":"WATSON","year":"1948","journal-title":"Obstetrical Gynecol. Surv."},{"key":"10.1016\/j.ymthe.2025.03.016_bib69","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00005792-200109000-00007","article-title":"Pharmacologic modulation of fetal hemoglobin","volume":"80","author":"Steinberg","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymthe.2025.03.016_bib70","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.2011.08916.x","article-title":"Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin","volume":"156","author":"Ngo","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib71","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0022-2836(71)90292-0","article-title":"Ligand-induced conformational dependence of hemoglobin in sickling interactios","volume":"60","author":"Bookchin","year":"1971","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib72","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1073\/pnas.77.9.5130","article-title":"Solubilization of hemoglobin S by other hemoglobins","volume":"77","author":"Benesch","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.016_bib73","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1126\/science.1065806","article-title":"Correction of sickle cell disease in transgenic mouse models by gene therapy","volume":"294","author":"Pawliuk","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib74","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene Therapy in a Patient with Sickle Cell Disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib75","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41591-021-01650-w","article-title":"Long-term outcomes of lentiviral gene therapy for the \u03b2-hemoglobinopathies: the HGB-205 trial","volume":"28","author":"Magrin","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib77","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.omtm.2019.01.005","article-title":"High-Efficiency Lentiviral Transduction of Human CD34(+) Cells in High-Density Culture with Poloxamer and Prostaglandin E2","volume":"13","author":"Uchida","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib78","article-title":"Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor","volume":"105","author":"Uchida","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2025.03.016_bib79","series-title":"Bluebird Bio Announces Temporary Suspension on Phase 1\/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (Bb1111) [Press Release]. Bluebird Bio","author":"Snyder","year":"2021"},{"key":"10.1016\/j.ymthe.2025.03.016_bib80","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.016_bib81","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib82","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.2021011121","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"138","author":"Pincez","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib83","first-page":"1185","article-title":"Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation","volume":"135","author":"Ghannam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib84","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1073\/pnas.76.2.670","article-title":"Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S","volume":"76","author":"Nagel","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.016_bib85","doi-asserted-by":"crossref","first-page":"27518","DOI":"10.1074\/jbc.M402578200","article-title":"A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin","volume":"279","author":"Levasseur","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.016_bib86","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/blood-2003-04-1251","article-title":"Correction of a mouse model of sickle cell disease: lentiviral\/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells","volume":"102","author":"Levasseur","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib87","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.omtm.2018.07.012","article-title":"An Optimized Lentiviral Vector Efficiently Corrects the Human Sickle Cell Disease Phenotype","volume":"10","author":"Weber","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib88","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2021-152331","article-title":"Clinical Results of the Drepaglobe Trial for Sickle Cell Disease Patients","volume":"138","author":"Magrin","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib89","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2009-01-201863","article-title":"A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction","volume":"114","author":"Perumbeti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.55","article-title":"Pigtailed macaques as a model to study long-term safety of lentivirus vector-mediated gene therapy for hemoglobinopathies","volume":"1","author":"Kiem","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib91","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood-2021-147469","article-title":"Safety and Efficacy of Aru-1801 in Patients with Sickle Cell Disease: Early Results from the Phase 1\/2 Momentum Study of a Modified Gamma Globin Gene Therapy and Reduced Intensity Conditioning","volume":"138","author":"Grimley","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib92","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib93","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ymthe.2019.05.014","article-title":"Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates","volume":"27","author":"Romero","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib94","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","article-title":"Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells","volume":"125","author":"Hoban","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib95","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-024-49353-3","article-title":"Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells","volume":"15","author":"Moiani","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib96","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2021.02.022","article-title":"Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease","volume":"21","author":"Uchida","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf2444","article-title":"Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease","volume":"13","author":"Lattanzi","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib98","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nprot.2017.143","article-title":"CRISPR\/Cas9 genome editing in human hematopoietic stem cells","volume":"13","author":"Bak","year":"2018","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2025.03.016_bib99","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells","volume":"539","author":"Dever","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib100","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib101","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2021-152892","article-title":"Cedar Trial in Progress: A First in Human, Phase 1\/2 Study of the Correction of a Single Nucleotide Mutation in Autologous HSCs (GPH101) to Convert HbS to HbA for Treating Severe SCD","volume":"138","author":"Kanter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib102","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nbt1353","article-title":"Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery","volume":"25","author":"Lombardo","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib103","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.stem.2022.09.001","article-title":"Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells","volume":"29","author":"Ferrari","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2025.03.016_bib104","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/0005-2795(70)90297-7","article-title":"Hemoglobin G Makassar: \u03b26 Glu\u2192Ala","volume":"214","author":"Quentin Blackwell","year":"1970","journal-title":"Biochim. Biophys. Acta (Bba) - Protein Struct."},{"key":"10.1016\/j.ymthe.2025.03.016_bib105","first-page":"577","article-title":"Hb G Makassar (beta 6:Glu-Ala) in a Thai family","volume":"85","author":"Sangkitporn","year":"2002","journal-title":"J.\u00a0Med. Assoc. Thai"},{"key":"10.1016\/j.ymthe.2025.03.016_bib106","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib107","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41551-023-01026-0","article-title":"Ex\u00a0vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice","volume":"7","author":"Everette","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2025.03.016_bib108","first-page":"2085","article-title":"In\u00a0vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib109","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41587-024-02264-6","article-title":"FDA clears prime editors for testing in humans","volume":"42","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib110","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib111","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","article-title":"Genotoxic effects of base and prime editing in human hematopoietic stem cells","volume":"42","author":"Fiumara","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib112","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/ajts.AJTS_71_16","article-title":"Hereditary persistence of fetal hemoglobin","volume":"14","author":"Sharma","year":"2020","journal-title":"Asian J. Transfus. Sci."},{"key":"10.1016\/j.ymthe.2025.03.016_bib113","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1136\/bmj.1.4925.1308","article-title":"Expression of the sickle-cell gene in Africa","volume":"1","author":"Edington","year":"1955","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ymthe.2025.03.016_bib114","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1101\/gad.1897310","article-title":"Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6","volume":"24","author":"Xu","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib115","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib116","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib117","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib118","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib119","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.omtm.2018.08.003","article-title":"Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with \u03b2-Thalassemia Major","volume":"10","author":"Psatha","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib120","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-74716-7","article-title":"Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease","volume":"14","author":"Lessard","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.016_bib121","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","article-title":"Therapeutic base editing of human hematopoietic stem cells","volume":"26","author":"Zeng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib122","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/bloodadvances.2020003702","article-title":"In\u00a0vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal \u03b3-globin in \u03b2-YAC mice","volume":"5","author":"Li","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.016_bib123","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1038\/ncomms8085","article-title":"Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin","volume":"6","author":"Wienert","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib124","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1038\/s41467-022-34493-1","article-title":"Base-editing-mediated dissection of a \u03b3-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression","volume":"13","author":"Antoniou","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib125","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib126","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1182\/blood-2023-187397","article-title":"AsCas12a Gene Editing of HBG1\/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia","volume":"142","author":"Hanna","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib127","author":"Editas Medicine","year":"2024","journal-title":"Editas Medicine Announces Strategic Transition to in vivo\u00a0Gene Editing Company with Intent to Achieve Human Proof of Concept in\u00a0Approximately Two Years"},{"key":"10.1016\/j.ymthe.2025.03.016_bib128","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1182\/blood-2024-204888","article-title":"Initial Results from the BEACON Clinical Study: A Phase 1\/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises","volume":"144","author":"Gupta","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib129","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s13213-012-0559-8","article-title":"Effects and applications of sub-lethal ultrasound, electroporation and UV radiations in bioprocessing","volume":"63","author":"Yeo","year":"2013","journal-title":"Ann. Microbiol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2174\/156652309788921062","article-title":"Electroporation advances in large animals","volume":"9","author":"Reed","year":"2009","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib131","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood-2016-04-711580","article-title":"In\u00a0vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors","volume":"128","author":"Richter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib132","article-title":"Nanoparticles targeting hematopoietic stem and progenitor cells: Multimodal carriers for the treatment of hematological diseases","volume":"4","author":"Cruz","year":"2022","journal-title":"Front. Genome"},{"key":"10.1016\/j.ymthe.2025.03.016_bib133","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature25022","article-title":"From haematopoietic stem cells to complex differentiation landscapes","volume":"553","author":"Laurenti","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib134","article-title":"Genomic Engineering in Human Hematopoietic Stem Cells: Hype or Hope?","volume":"2","author":"Klaver-Flores","year":"2020","journal-title":"Front. Genome"},{"key":"10.1016\/j.ymthe.2025.03.016_bib135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coviro.2016.08.017","article-title":"Adenovirus sensing by the immune system","volume":"21","author":"Atasheva","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib136","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.1201219","article-title":"Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment","volume":"333","author":"Notta","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1031334","article-title":"Antibody based conditioning for allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Saha","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib138","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib139","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.omtm.2019.10.010","article-title":"Immunoresponse to Gene-Modified Hematopoietic Stem Cells","volume":"16","author":"Drysdale","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib140","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib141","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib142","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1038\/s41467-023-41153-5","article-title":"Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model","volume":"14","author":"Uchida","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib143","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1182\/blood-2022-162406","volume":"140","author":"Westervelt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib144","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2021015246","article-title":"Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML","volume":"141","author":"Roas","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib145","article-title":"Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantation","author":"Yelamali","year":"2024","journal-title":"bioRxiv."},{"key":"10.1016\/j.ymthe.2025.03.016_bib146","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/bloodadvances.2019001289","article-title":"Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"4","author":"Abadir","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.016_bib147","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/vir.0.19497-0","article-title":"Genetic content and evolution of adenoviruses","volume":"84","author":"Davison","year":"2003","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib148","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/44880","article-title":"A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein","volume":"401","author":"van Raaij","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib149","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1128\/jvi.68.6.4104-4106.1994","article-title":"Cell-binding domain of adenovirus serotype 2 fiber","volume":"68","author":"Louis","year":"1994","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib150","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/j.1460-2075.1983.tb01592.x","article-title":"Evidence for a repeating cross-beta sheet structure in the adenovirus fibre","volume":"2","author":"Green","year":"1983","journal-title":"Embo j"},{"key":"10.1016\/j.ymthe.2025.03.016_bib151","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib152","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib153","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib154","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib155","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.016_bib156","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omtm.2021.12.003","article-title":"Safe and efficient in\u00a0vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5\/35++ vectors","volume":"24","author":"Li","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib157","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/bloodadvances.2022007975","article-title":"In\u00a0vivo HSC transduction in rhesus macaques with an HDAd5\/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4","volume":"6","author":"Wang","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.016_bib158","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2018-03-838540","article-title":"Reactivation of \u03b3-globin in adult \u03b2-YAC mice after ex\u00a0vivo and in\u00a0vivo hematopoietic stem cell genome editing","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib159","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood.2020010020","article-title":"Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in\u00a0vitro and in\u00a0vivo","volume":"138","author":"Psatha","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib160","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.ymthe.2024.10.018","article-title":"Introducing a hemoglobin G-Makassar variant in HSCs by in\u00a0vivo base editing treats sickle cell disease in mice","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib161","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood-2024-203662","article-title":"In\u00a0Vivo Hematopoietic Stem Cell Engineering Restores the Function of NADPH Enzyme Complex in X-Linked Chronic Granulomatous Disease Model Mice","volume":"144","author":"Kattula","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib162","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12015-015-9625-5","article-title":"Emerging Strategies to Enhance Homing and Engraftment of Hematopoietic Stem Cells","volume":"12","author":"Ratajczak","year":"2016","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.ymthe.2025.03.016_bib163","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.cell.2022.04.039","article-title":"Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells","volume":"185","author":"Omer-Javed","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.016_bib164","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0958-1669(02)00374-9","article-title":"No false start for novel pseudotyped vectors","volume":"13","author":"Sanders","year":"2002","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0411","article-title":"Sustained fetal hemoglobin induction in\u00a0vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor","volume":"13","author":"Uchida","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib166","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.016_bib167","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1016\/j.biomaterials.2014.01.051","article-title":"Systematic improvement of lentivirus transduction protocols by antibody fragments fused to VSV-G as envelope glycoprotein","volume":"35","author":"H\u00f6fig","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2025.03.016_bib168","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/mthe.2000.0116","article-title":"VSV-G Pseudotyped Lentiviral Vector Particles Produced in Human Cells Are Inactivated by Human Serum","volume":"2","author":"DePolo","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib169","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/mt.2009.282","article-title":"Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells","volume":"18","author":"Trobridge","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0092-8674(93)80071-L","article-title":"The human CD46 molecule is a receptor for measles virus (Edmonston strain)","volume":"75","author":"D\u00f6rig","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.016_bib171","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/35022579","article-title":"SLAM (CDw150) is a cellular receptor for measles virus","volume":"406","author":"Tatsuo","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib172","doi-asserted-by":"crossref","DOI":"10.3390\/v14102157","article-title":"Adapter-Mediated Transduction with Lentiviral Vectors: A Novel Tool for Cell-Type-Specific Gene Transfer","volume":"14","author":"Cordes","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.016_bib173","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1006\/jmbi.2000.3543","article-title":"Paramyxovirus F1 protein has two fusion peptides: implications for the mechanism of membrane fusion","volume":"296","author":"Peisajovich","year":"2000","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib174","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1182\/bloodadvances.2017007773","article-title":"Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent","volume":"1","author":"L\u00e9vy","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.016_bib175","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.omtm.2023.02.004","article-title":"A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin","volume":"28","author":"Vamva","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102318","article-title":"Cell-targeted gene modification by delivery of CRISPR-Cas9 ribonucleoprotein complexes in pseudotyped lentivirus-derived nanoparticles","volume":"35","author":"Nielsen","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.03.016_bib177","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1182\/blood-2008-05-155945","article-title":"Stable transduction of quiescent T\u00a0cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins","volume":"112","author":"Frecha","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib178","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2017.03.005","article-title":"Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells","volume":"5","author":"Wang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib179","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","article-title":"Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors","volume":"13","author":"Jamali","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.016_bib180","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jmv.21649","article-title":"Pro-inflammatory response resulting from sindbis virus infection of human macrophages: Implications for the pathogenesis of viral arthritis","volume":"82","author":"Assun\u00e7\u00e3o-Miranda","year":"2010","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib181","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1128\/JVI.74.19.9294-9299.2000","article-title":"Sindbis-group alphavirus replication in periosteum and endosteum of long bones in adult mice","volume":"74","author":"Heise","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib182","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1128\/jvi.67.6.3363-3374.1993","article-title":"Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells","volume":"67","author":"Dubuisson","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib183","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2005.04.039","article-title":"Targeting Sindbis virus-based vectors to Fc receptor-positive cell types","volume":"338","author":"Klimstra","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2025.03.016_bib184","doi-asserted-by":"crossref","first-page":"e01860-17","DOI":"10.1128\/mBio.01860-17","article-title":"Retargeting Lentiviruses via SpyCatcher-SpyTag Chemistry for Gene Delivery into Specific Cell Types","volume":"8","author":"Kasaraneni","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.ymthe.2025.03.016_bib185","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nm1192","article-title":"Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection","volume":"11","author":"Morizono","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib186","doi-asserted-by":"crossref","first-page":"e02990-19","DOI":"10.1128\/mBio.02990-19","article-title":"Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies","volume":"11","author":"Parker","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.ymthe.2025.03.016_bib187","article-title":"Bispecific binder redirected lentiviral vector enables in\u00a0vivo engineering of CAR-T cells","volume":"9","author":"Huckaby","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.016_bib188","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In\u00a0vivo generated human CAR T\u00a0cells eradicate tumor cells","volume":"8","author":"Agarwal","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2025.03.016_bib189","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In\u00a0vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib190","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib191","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in\u00a0vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib192","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in\u00a0vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.016_bib193","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in\u00a0vivo","volume":"42","author":"An","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib194","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.2022019333","article-title":"Lipid nanoparticles allow efficient and harmless ex\u00a0vivo gene editing of human hematopoietic cells","volume":"142","author":"Vavassori","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.016_bib195","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00277-019-03713-y","article-title":"Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in\u00a0vivo","volume":"98","author":"Jyotsana","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib196","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In\u00a0Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib197","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.03.016_bib198","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","article-title":"Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs","volume":"8","author":"Dilliard","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2025.03.016_bib199","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.016_bib200","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib201","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.016_bib202","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In\u00a0vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib203","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In\u00a0vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.016_bib204","article-title":"Developing single-course gene editing medicines to treat cardiovascular disease. In: European Society of Cell and Gene Therapy 31st AnnualCongress.","author":"Khera","year":"2024","journal-title":"INV04."},{"key":"10.1016\/j.ymthe.2025.03.016_bib205","doi-asserted-by":"crossref","first-page":"17095","DOI":"10.1021\/jacs.8b08976","article-title":"Nanoparticles That Deliver RNA to Bone Marrow Identified by in\u00a0Vivo Directed Evolution","volume":"140","author":"Sago","year":"2018","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2025.03.016_bib206","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1038\/s41467-022-32281-5","article-title":"Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in\u00a0vivo","volume":"13","author":"Ni","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.016_bib207","first-page":"1","article-title":"Lipid nanoparticle-mediated mRNA delivery to CD34(+) cells in rhesus monkeys","author":"Kim","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.016_bib208","series-title":"Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-Based in\u00a0Vivo Editing of Bone Marrow at Keystone eSymposium [Press Release]","author":"Goddard","year":"2021"},{"key":"10.1016\/j.ymthe.2025.03.016_bib209","article-title":"In\u00a0vivo genome editing of human hematopoietic stem cells for treatment of blood disorders by mRNA delivery","author":"Xu","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2025.03.016_bib210","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1021\/acs.nanolett.3c00304","article-title":"In\u00a0Vivo RNA Delivery to Hematopoietic Stem and Progenitor Cells via Targeted Lipid Nanoparticles","volume":"23","author":"Shi","year":"2023","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2025.03.016_bib211","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061603","article-title":"Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles","volume":"15","author":"Swart","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2025.03.016_bib212","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In\u00a0vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.016_bib213","first-page":"280","article-title":"In\u00a0Vivo HSC Gene Editing for Correction of Sickle Cell Mutation Using RNA Gene Writers","volume":"32","author":"Schiroli","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.016_bib214","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2024-208626","article-title":"In\u00a0Vivo HSC Gene Editing for Correction of the Sickle Cell Mutation Using RNA Gene Writers","volume":"144","author":"Tozzi","year":"2024","journal-title":"Blood"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500190X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500190X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:38:20Z","timestamp":1792687100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162500190X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":214,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S152500162500190X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.016","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in\u00a0vivo gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}